Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 18,757 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions: Brentuximab Vedotin, Cyclosporine, Pharmacokinetic Study, Verapamil, Verapamil Hydrochloride; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 15 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Duarte, California

Conditions: Healthy Volunteer
Interventions: AZD1722, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Cypress, California

Conditions: Solid Tumors
Interventions: BKM120 days 1 - 21 plus paclitaxel + carboplatin, BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin, BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1), BKM120, Paclitaxel + Carboplatin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer, Non-Small Cell Lung Cancer
Interventions: Dasatinib, Erlotinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Refractory Head and Neck Cancer, Squamous Cell Carcinoma, Skin, Carcinoma of the Breast, Malignant Melanoma
Interventions: HF10; Drug
Lead sponsor: Takara Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 5
States / cities: The Bronx, New York • Portland, Oregon • Pittsburgh, Pennsylvania + 2 more

Conditions: Impaired Hepatic Function, Healthy
Interventions: ALXN2050; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Conditions: Diabetes Mellitus
Interventions: JTT-251 or Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Central Serous Chorioretinopathy
Interventions: rhuFab V2 [ranibizumab] ( Lucentis ); Drug
Lead sponsor: Vitreous -Retina- Macula Consultants of New York; Other
Eligibility: Not listed
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Myasthenia Gravis, Muscle Weakness
Interventions: anito-cel, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 14
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 10 more

Conditions: Brain Neoplasms
Interventions: MPC-6827; Drug
Lead sponsor: Myrexis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumor
Interventions: XTX301; Drug
Lead sponsor: Xilio Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: Sacramento, California • New Haven, Connecticut • Saint Louis Park, Minnesota + 9 more

Conditions: Chordoma
Interventions: Imatinib + LBH589; Drug
Lead sponsor: Deric M Park MD; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Charlottesville, Virginia

Conditions: Peritoneal Neoplasms, Stomach Neoplasms
Interventions: CHPP with cisplatin; Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Psoriasis
Interventions: Calcipotriene 0.005% Foam; Drug
Lead sponsor: Mayne Pharma International Pty Ltd; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 36
States / cities: Birmingham, Alabama • Rogers, Arkansas • Encino, California + 30 more

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: Dolastatin 10; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Neoplasm, Hereditary Nonpolyposis
Interventions: Celecoxib (SC-58635); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia
Interventions: alemtuzumab, fludarabine phosphate; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 50
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 31 more

Conditions: X-linked Severe Combined Immunodeficiency, X-SCID, XSCID
Interventions: Plerixafor, Filgrastim, Palifermin, Busulfan, Base-edited hematopoietic stem and progenitor cells; Genetic · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 99 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: 7-hydroxystaurosporine, prednisone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 3
States / cities: Bethesda, Maryland • Frederick, Maryland

Conditions: Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer, Stage II Lung Cancer, Stage III Lung Cancer
Interventions: Cisplatin, Carboplatin, Etoposide, Pembrolizumab, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Radiation Therapy; Drug · Biological · Procedure + 1 more
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Solid Tumors
Interventions: PM060184; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Cancer
Interventions: capecitabine, ixabepilone; Drug
Lead sponsor: R-Pharm; Industry
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: GEM 231, docetaxel; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Recurrent or Metastatic Solid Tumors
Interventions: Ifinatamab deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Los Angeles, California • Whittier, California • Skokie, Illinois + 13 more

Search by objective public record fields.

Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Study of ALXN2050 in Participants With Hepatic Impairment

Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases

Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases

XTX301 in Patients With Advanced Solid Tumors

Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma

Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis

Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis

Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers

Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma

Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer

Study of PM060184 in Patients With Advanced Solid Tumors

BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer

Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)